PTGS2 and breast cancer: In 2022, Khella et al. [56] evaluated the anticancer activity of CA in breast cancer cells (MCF-7) and colon cancer cells (Caco-2) by measuring the cell viability, apoptosis rate, and gene expression of key biomarkers such as GCLC, COX-2, and BCL-2.